EFSA’s 2026 CBD Novel Food Opinion: Safety Assessment, EU Authorization And Compliance Guide

What EFSA’s Provisional Safe Intake Level Means for CBD Manufacturers, Importers and Food Supplement Businesses

In September 2026, the European Food Safety Authority (EFSA) published a positive scientific opinion on the safety of synthetic cannabidiol (CBD) as a Novel Food under Regulation (EU) 2015/2283. The assessment concluded that the specific CBD ingredient could be considered safe at an intake of up to 2 mg per day under defined conditions of use. The opinion was published on 18 September 2026 and amended on 21 September 2026.

However, a positive EFSA scientific opinion does not automatically authorize a CBD product for sale in the European Union (EU). Novel Food authorization remains a separate regulatory step, and the assessment applies only to the specific ingredient and conditions evaluated.

For CBD manufacturers, food supplement brands, ingredient suppliers and importers, this development highlights the importance of toxicological evidence, product characterization, analytical testing and regulatory compliance before placing CBD-containing products on the EU market.

Why EFSA’s CBD Safety Opinion Matters

Cannabidiol is a non-intoxicating cannabinoid derived from Cannabis sativa or produced through chemical synthesis. It is used in products proposed for food supplements and other consumer applications.

Under the EU Novel Food Regulation, food without a significant history of consumption in the EU before 15 May 1997 may require authorization before they can be marketed.

CBD ingredients have presented regulatory challenges because of uncertainties concerning their toxicological profile, production processes, composition and potential effects on human health.

EFSA’s 2026 opinion provides a more specific scientific conclusion for the synthetic CBD ingredient assessed, but important conditions and limitations remain.

What Did EFSA Conclude in September 2026?

EFSA assessed synthetic cannabidiol intended for use in food supplements. The ingredient had a CBD purity of at least 98% and was proposed for use dissolved in medium-chain triglyceride (MCT) oil.

The assessment established a provisional safe intake level under the proposed conditions of use.

The conclusion is specific to the ingredient, formulation and conditions assessed. Companies should not assume that the same conclusion applies to all CBD extracts, isolates, synthetic ingredients or finished products.

Understanding the 2 mg Daily Intake Level

EFSA’s provisional safe intake level is based on toxicological evidence and an uncertainty factor intended to account for remaining data gaps.

The assessment identified the liver as a key target organ in the submitted subchronic toxicity study. Uncertainties also remain concerning reproductive and developmental toxicity and other potential health effects.

The 2 mg daily level should therefore be understood as a conditional scientific safety benchmark, not a universally applicable recommended dose or a general approval for CBD products.

Manufacturers should consider the following when evaluating their products:

• CBD concentration and purity.
• Daily serving size and maximum recommended intake.
• Formulation and delivery system.
• Presence or absence of nanoparticles.
• Manufacturing process and impurity profile.
• Target population and product labelling.
• Potential interactions with medicines.

What Does This Mean for CBD Novel Food Authorization?

A scientific opinion from EFSA and a legal authorization from the European Commission are different stages of the EU Novel Food process.

A positive EFSA opinion should not be interpreted as permission to market every CBD-containing food supplement. Businesses should verify the status of the specific ingredient and application and confirm whether an applicable authorization has been granted.

Why Analytical Testing Is Essential for CBD Products

Analytical testing is an important part of demonstrating that a CBD ingredient meets its specifications and that the composition of the finished product is consistent with the supporting regulatory documentation.

Depending on the ingredients and product, a risk-based testing programme may include:

• CBD identity and assay: Confirming the identity and concentration of cannabidiol.
• Cannabinoid profiling: Evaluating relevant cannabinoids and potential impurities.
• Residual solvents: Assessing solvent residues associated with extraction or manufacturing.
• Contaminant testing: Evaluating relevant heavy metals, pesticides and other contaminants based on the source and process.
• Impurity characterization: Investigating process-related impurities and degradation products.
• Stability testing: Assessing whether the ingredients and finished product remain within specifications throughout shelf life.
• Method validation: Establishing that analytical methods are suitable for their intended purpose.

Testing requirements should be determined by the ingredient's manufacturing process, risk profile, proposed use and applicable regulatory specifications. Analytical results alone do not establish Novel Food authorization or prove overall safety.

Who Should Review Their CBD Compliance Strategy?

The EFSA opinion is particularly relevant to businesses involved in developing, manufacturing or supplying CBD ingredients and products.

2026 CBD Novel Food Compliance Readiness Checklist

Companies should establish a documented, product-specific assessment before proceeding with EU market entry.

Practical CBD Regulatory Compliance Roadmap

A structured implementation approach can help businesses identify gaps and prepare stronger regulatory submissions.

1. Identify CBD ingredients and finished products intended for the EU market.
2. Confirm the ingredient's source, production process, identity and composition.
3. Determine the applicable Novel Food requirements and current authorization status.
4. Review the available toxicological evidence and identify missing studies.
5. Assess CBD intake, serving sizes and proposed conditions of use.
6. Establish suitable analytical testing and product specifications.
7. Collect supplier records, certificates of analysis and manufacturing documentation.
8. Evaluate product labelling and other applicable food law obligations.
9. Document regulatory gaps and develop a corrective action plan.
10. Monitor regulatory developments and maintain ongoing compliance controls.

Frequently Asked Questions

1. What did EFSA announce in September 2026?

EFSA published a positive scientific opinion on a specific synthetic CBD ingredient proposed for food supplements, concluding that it was safe at up to 2 mg per day under defined conditions.

2. Does the EFSA opinion authorize CBD products in the EU?

No. A positive scientific opinion is not itself a market authorization. Businesses must verify the applicable European Commission decision and legal conditions.

3. Does the 2 mg level apply to all CBD products?

No. The assessment concerns a specific ingredient and proposed conditions of use. It should not automatically be applied to all CBD extracts, isolates or finished products.

4. Which groups are excluded from the assessment?

The assessed conditions exclude individuals under 25 years of age and pregnant or lactating women. Safety could not be established for people taking medication.

5. Why is analytical testing important?

Testing helps verify ingredient identity, purity, cannabinoid content, relevant contaminants and compliance with product specifications. It supports, but does not replace, the overall safety assessment and authorization process.

6. Should CBD manufacturers review existing products?

Yes. Businesses should reassess ingredient specifications, formulation, daily intake, supporting safety data and regulatory status before making market-entry or product-compliance decisions.

Conclusion

EFSA’s September 2026 scientific opinion on synthetic CBD represents an important development in the assessment of cannabidiol as a Novel Food in the EU. The provisional safe intake level of 2 mg per day applies only under specific conditions, and significant limitations remain for certain populations.

For manufacturers, importers and food supplement businesses, the next steps should include verifying the ingredient's regulatory status, reviewing toxicological evidence, establishing appropriate analytical testing and maintaining complete product documentation.

A proactive, evidence-based approach can help organizations identify compliance gaps and prepare for the evolving regulatory requirements governing CBD-containing food supplements.

How Maven Regulatory Solutions Can Help

Maven Regulatory Solutions can support businesses with:

• CBD Novel Food regulatory assessments.
• EU regulatory pathway and authorization reviews.
• Toxicological risk assessment support.
• Product composition and specification reviews.
• Analytical testing strategy and documentation reviews.
• Supplier qualification and compliance assessments.
• Regulatory gap assessments.
• Product labelling and documentation reviews.
• Regulatory intelligence and lifecycle compliance support.

Our approach helps manufacturers and importers evaluate CBD-related regulatory risks, strengthen supporting evidence and develop practical compliance strategies for the European market.